Artiva Biotherapeutics, Inc. (ARTV), a clinical-stage biotechnology company, Tuesday announced that it has appointed Thad Huston as its Chief Financial Officer.
Huston has more than 30 years of global leadership experience spanning finance, commercial strategy, business development and operations across public companies in pharmaceuticals, biotechnology and medical devices.
Most recently, he was the chief financial officer and chief operating officer at Galapagos.
In pre-market activity, ARTV shares are trading at $4.68, down 2.33% on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.